
CBO Estimate of the Statutory Pay-As-You-Go Effects for S. 3187, the Food and Drug Administration Safety and Innovation Act, with an Amendment, as posted on the Web site of the House Committee on Energy and Commerce on June 18, 2012

	By Fiscal Year, in Millions of Dollars												2012 -	2012 -
	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2017	2022	
NET INCREASE OR DECREASE (-) IN THE DEFICIT														
Statutory Pay-As-You-Go Impact	0	-16	-14	-20	-27	-37	-34	7	-39	-69	-63	-113	-311	

Source: Congressional Budget Office.

Notes: Components may not sum to totals because of rounding.

S. 3187, with the proposed amendment, would modify how the Food and Drug Administration regulates drugs and devices in a broad range of areas. Several provisions would affect when lower-priced drugs enter the market. Changing the timing of availability of lower-priced drugs affects spending in federal health programs that pay for prescription drugs and biological products. It would also reduce the costs of health insurance plans and thus reduce federal subsidies for health insurance purchased through an exchange. On net, the legislation would result in a reduction in the deficit of \$113 million over the 2012-2017 period, which is the sum of a reduction in direct spending of \$112 million and an increase in revenues of \$1 million. Similarly, the 10-year net reduction in deficits of \$311 million is the sum of a reduction in direct spending of \$307 million and an increase in revenues of \$4 million.
